Sign in
Not yet recruitingNo phase

Real-World Effectiveness of Cabozantinib in Advanced Neuroendocrine Tumors: A Retrospective Multicenter Study Using the GTE-RENATEN National Database

Key facts

Who runs it
Hospices Civils de Lyon
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
150 people, planned
Starts
Dec 2026
Expected to end
7 Jan 2028
Type of study
Observational
Record updated
16 November 2026

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (6)Hide the full registry criteria

Who can take part

  • Adults ≥18 years
  • Histologically confirmed, well-differentiated NET (G1-G3) or typical/atypical thoracic carcinoids
  • Metastatic or unresectable disease
  • Cabozantinib initiated between January 2020 and August 2026

Who cannot take part

  • Poorly differentiated neuroendocrine carcinoma (NEC), including MiNEN with NEC component
  • Missing data for the cabozantinib: date of start or date of stop

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Advanced neuroendocrine carcinoma

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Neuroendocrine tumors are rare tumors with prolonged survival. The management of patients at advanced stage is centered on both locoregional control and systemic therapy. Systemic approaches include somatostatin analogs (SSA) that improve symptom control and slow tumor progression, peptide receptor radionuclide therapy (PRRT), targeted agents (everolimus, sunitinib and cabozantinib) and chemotherapy. All these therapies have demonstrated clinical benefit across multiple randomized and non-randomized studies, yet no high-level evidence defines the optimal sequence in which they should be administered in real-world metastatic settings.

Read full original descriptionShow less

The recent approval of cabozantinib, a multikinase inhibitor targeting VEGFR, MET, and AXL, represents a major advancement in the systemic management of NETs.

The retrospective study "CARE-NET", is a multicenter study which has the aims to describe the real-world use of cabozantinib (between January 2020 and August 2026) in France.

The group in the trial

  • Advanced Neuroendocrine Tumors treated by cabozantinib follow in ENDOCAN RENATEN network

    Adults ≥18 years. Histologically confirmed, well-differentiated NET (G1-G3) or typical/atypical thoracic carcinoids Metastatic or unresectable disease. Cabozantinib initiated between January 2020 and August 2026

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07939113, who can take part
Record updated
16 November 2026